Severe aplastic anemia (SAA) is a BM failure syndrome in which allo-SCT remains a highly effective curative option. Its application remains limited by donor availability and by the potential for treatment-related morbidity and mortality. The improved outcomes with unrelated transplantation are a result of the advent of molecular donor-recipient matching, generation of effective novel conditioning regimens, improvement of supportive care and expansion of the donor registry. Decision making regarding the earlier use of unrelated transplant procedures is rapidly evolving. This paper reviews critical data relevant to these treatment options and recommends early consideration of related SCT for patients with SAA who show failure of immune suppressive therapy.
Introduction
Acquired severe aplastic anemia (SAA) is a rare, lifethreatening condition of BM failure with profound pancytopenia associated with a markedly hypoproliferative marrow, due to stem cell loss secondary to drug, viral and/ or immunological origins. Patients with SAA present with complications related to pancytopenia, including bleeding, infections and significant anemia; prompt recognition of these complications leads to appropriate, emergent therapy. Key features of early management include the use of broad spectrum antimicrobials for empiric treatment of neutropenic infections; irradiation and filtration of all blood and plt products to prevent transfusion-associated complications such as CMV infection and transfusion-associated GVHD; early involvement of a center experienced in the management of SAA and BMT; and rapid search of family members for potential BMT donors.
The current standards for the initial therapy for patients with SAA include either allogeneic BMT or immunosuppressive therapy, and the choice between these two depends on numerous factors, including recipient age, status of related donors and access to medical care. 1 As shown both in single institution and retrospective registry series, in young patients under the age of 50 years with a matched related donor, allogeneic BMT after conditioning with CY and antithymocyte globulin (ATG) should be used as definitive therapy as quickly as possible (Figures 1, 2 ). This recommendation is based on the findings from numerous groups of excellent short-term and long-term outcomes in patients treated with this approach. [2] [3] [4] [5] [6] [7] [8] In patients aged 50-60 years with a matched sibling donor, up front transplantation should be strongly considered in the context of other comorbidities and complications. The major toxicities from allogeneic BMT that impact outcome include engraftment failure, infectious complications and GVHD. With the use of irradiated blood products and avoidance of blood products from family members in the pretransplant period, engraftment failure rates have dropped significantly, with current rates under 10%. [2] [3] [4] [5] [6] [7] [8] Outcomes of infectious complications are also improving with the expansion of antibacterial and antifungal therapies and preemptive treatment of CMV infection and disease. GVHD remains to be the major factor impacting outcomes of matched related donor transplantation for SAA. As shown by Locatelli et al. 7 ( Figure 3 ), patients with grade 0-I acute GVHD fared significantly better than those with grade II-III acute GVHD, with long-term survival approaching 98% without significant GVHD vs only 70% with higher-grade acute GVHD (P ¼ 0.0017). In efforts to preemptively reduce the risk of GVHD, investigators at the Seattle Cancer Care Alliance have retrospectively evaluated their GVHD rates on the basis of stem cell dose numbers and have found that rates of GVHD correlate with marrow total mononuclear cell doses, in which circumstances, where total marrow cell dose was greater than 3.4 Â 10 8 cells per kg, outcomes were significantly compromised because of the increase in chronic GVHD rates. 2 Unfortunately, the data regarding CD34 þ and CD3 þ cell doses were not available for analysis in this paper, but as this observation was unexpected, the Seattle group has established an ongoing study of stem cell dose modification in patients with SAA receiving matched sibling transplants. In summary, for otherwise healthy patients less than 50 years old with matched related donors, allogeneic BMT is considered to be the first-line therapy for management of SAA. The main progress in the field has been focused on the study of preemptive strategies to reduce GVHD, which remains the major factor negatively influencing long-term outcome.
Unfortunately, most patients do not have a matched related donor, and therefore immunosuppression with ATG and CYA-based therapy is initiated as first-line therapy. Immunosuppressive therapy with ATG and CYA leads to improvement in counts for B50-60% of patients, yet there are a number of drawbacks. These include extended time to first response (1-4 months), as evidenced by neutrophil and plt count improvements; the need for prolonged or lifetime immunosuppressive therapy for many patients, [9] [10] [11] with one group showing the ongoing use of immune suppressive medications in many patients for up to 10 years from diagnosis; 10 the risk of relapse; and the significant risk for the development of clonal hematopoietic disorders, in particular myelodysplasia, leukemia and paroxysmal nocturnal hemoglobinuria. Despite these shortfalls, most clinicians will maximize their use of immunosuppressive therapy with a second or third course of treatment before pursuit of an unrelated donor hematopoietic SCT (HSCT). This practice relates to the concern of significant early TRM associated with allogeneic BMT using an alternative donor. However, there are key findings that lead one to reconsider this practice (Figure 4) , as shown by recent National Marrow Donor Program retrospective analyses of children and adults, which clearly show improvements in the outcomes in allogeneic BMT patients who use an unrelated donor when measured over the past two decades (Figures 5, 6 ). In addition, there is high disease-related mortality within the first year from diagnosis in those patients who fail to reconstitute hematopoiesis after treatment with immune suppressive therapy. 12 As evidence should be the basis of all practice decisions, newer data support consideration of earlier transplantation approaches in those patients without a matched related donor.
The management strategy to avoid unrelated HSCT in patients with SAA is based mainly on older data of outcomes from unrelated donor HSCT for SAA, in which standard conditioning included conventional dose TBI and previous high-resolution typing of unrelated donors. Recent studies have analyzed the impact of high-resolution typing of donors and clearly show a significant improvement in OS and lower rates of GVHD. 13, 14 In addition, manipulation of conditioning regimens to reduce therapyrelated toxicities without compromising engraftment rates Years after HCT Probability of survival and relapse are showing great promise. The goal of this review is to analyze the most recent data on unrelated donor transplantation for SAA and question the current approach in the management of patients with SAA who lack sibling donors. On the basis of these newer data, we will propose that an unrelated donor should be sought at the diagnosis of the disease and that patients who have failed a single course of immunosuppression, as defined by lack of reversal of the critical cytopenias that define SAA (ANC o0.5 Â 10 9 cells per L; plts o20 Â 10 9 cells per L), and are identified to have an 8/8 matched unrelated donor, should proceed with transplantation. In addition, the use of up front unrelated donor HSCT in the pediatric population and the expanding role for umbilical cord transplantation will be discussed.
Impact of high-resolution typing
A few recent large studies have reviewed the impact of highresolution molecular HLA typing on the outcomes in unrelated donor HSCT for SAA. 13, 14 These large studies have compared outcomes in the era before and after the availability of high-resolution typing. In addition, specific variables were analyzed that impact outcomes. The availability and use of molecular matched donors, as defined by high-resolution typing, were found to be statistically significant in predicting improved outcomes. These major studies evaluated engraftment failure, survival outcomes and rates of GVHD ( Table 1 ). The final study cited by Kojima et al, is an analysis of the Japan Registry data in the era of high-resolution typing of a predicted homogeneous donor: recipient pool. Interestingly, the outcomes observed were equivalent to the other post-1998 results obtained from Western Europe in which greater heterogeneity of the HLA loci of the donor: recipient pairs would be predicted. The most impressive finding is the significant improvement in OS in the recent era of treatment, as shown in both analyses of registry data by Maury et al. 13 and Viollier et al. 14 In the larger review by Viollier et al., the 5-year OS after 1998 was 57%, which was statistically significantly higher when compared with the pre-1998 era survival rate of 32% ( Figure 7 ). In addition, rates of engraftment failure (11 vs 26%), acute GVHD (28 vs 37%) and chronic GVHD (32 vs 57%) were all statistically significantly reduced in the more recent treatment era compared with the earlier treatment time, and these rates correlate well with the rates shown in Kojima's review, which found a graft failure rate of 5%, aGVHD of 29%, cGVHD of 30% and 5-year OS of 56%. 15 It should be noted that there were other treatment differences between the groups transplanted before 1998 and after 1998 in the Maury and Viollier trials. In the Viollier trial, conditioning regimens were more likely to contain fludarabine and less likely to contain TBI in the post-1998 era. In the Maury review, conditioning regimens Years from BMT Probability (%) Figure 3 The GITMO/EBMT performed a randomized trial assessing GVHD prophylaxis in BMT for SAA. In their analysis of the impact of GVHD on OS, they found significant differences between outcomes based on the extent of GVHD, as shown in this figure. Source: Locatelli et al. 7 Copyright American Society of Hematology.
Severe aplastic anemia were also more likely to contain fludarabine and ATG (or other MoAbs). Additional studies have documented the positive impacts on the outcomes with modifications of conditioning regimens, in particular with the introduction of fludarabine and reduction in TBI dosing.
Impact of conditioning regimen CY combined with myeloablative doses of TBI was historically the standard conditioning regimen for unrelated HSCT for SAA, although there are associated complications including early treatment-related toxicity and long-term toxicity, in particular secondary malignancies. Therefore, in an effort to reduce toxicity without negatively impacting engraftment, many groups have manipulated conditioning regimens to reduce TBI dosing with the introduction of agents such as ATG, alemtuzumab and fludarabine. [16] [17] [18] [19] [20] [21] An analysis from the Fred Hutchinson Cancer Research Center revealed that the standard regimen for related donor transplants, horse ATG combined with CY, was not an adequate conditioning for unrelated HSCT owing to high rates of engraftment failure. 22 Since that time many groups have introduced additional immunosuppressive agents, in particular fludarabine and alemtuzumab, with the goal of reducing the dose of TBI. With the focus shifting from complete myeloablation toward immunosuppression, consistent with the emergence of reduced-intensity transplantation as a highly efficacious intervention for hematological malignancies, it has similarly been observed that the toxicity profiles have been quite favorable, without compromise in engraftment rates. In addition, in review of chimerism data among reported experience with reduced-intensity transplantation for aplastic anemia, rapid establishment and maintenance of 100% donor chimerisms are found in 480% of patients studied, with rare autologous recovery noted. Although these studies are still early, one would theorize that long-term complications, in particular secondary malignancies, may be lower because of the reduction or removal of TBI. Table 2 outlines the major studies using fludarabine and alemtuzumab in the conditioning regimen for both unrelated and related donor transplants for SAA. These studies show very promising results for fludarabine-containing conditioning regimens, with good rates of engraftment and low treatment-related mortality.
The other novel conditioning agent that shows promise in reduced-intensity alternative donor HSCT for SAA is alemtuzumab. This agent has been studied in combination with fludarabine-containing conditioning regimens (Table 2 ) and also has been used in the absence of the purine analog. Alemtuzumab has the advantage of providing marked T-cell depletion, and can provide for improvements in engraftment as well as GVHD prevention when used in doses of 0.75-1 mg/kg total dosing. Two studies that highlight the use of alemtuzumab show good tolerance of the regimen with low treatment-related mortality and satisfactory engraftment rates. 18, 21 However, infection risks may be accentuated with the use of alemtuzumab, as its use has been associated with higher rates of CMV reactivation and has been linked to severe cases of EBV and adenovirus infection. [23] [24] [25] [26] [27] [28] [29] However, these early studies on SAA show a potential central role for alemtuzumab, in particular for control of both acute and chronic GVHD.
Currently, the BMT Clinical Trial Network has an ongoing Phase I/II trial for unrelated donor HSCT for SAA evaluating the effectiveness of a conditioning regimen of fludarabine, ATG and TBI (200 cGy), with a deescalation of the CY dose from 150 mg/kg to 0 mg/kg. The primary objective of this trial is to identify the lowest dose of CY that will permit effective engraftment, with the idea of reducing the short-and long-term toxicities of the conditioning regimen. Secondary objectives include post transplant survival, graft failure and rates of acute and chronic GVHD. The accrual goal for this trial is B80 patients, and although the enrollment has been slower than hoped, the trial has been consistently enrolling patients. The early findings from this trial show excess treatmentrelated toxicity in the highest dose of CY and engraftment failure with no CY. The trial is currently focused on the enrollment into the middle doses of CY, with anticipation of adequate numbers in these dosing cohorts to fully understand the benefits and risks of these regimens. The findings from this trial will markedly advance the field of unrelated transplantation for SAA through a detailed study of optimal conditioning with the integration of fludarabine and minimizing both TBI and CY doses.
How does current allogeneic transplantation compare with immunosuppressive treatment?
Historically studies comparing HSCT to immunosuppressive treatment (IST) have focused on OS. Clearly, this is an important outcome, but impacts on quality of life, economic burden, burden of disability and disease have rarely been addressed and need to be considered in the Years Cum survival Figure 7 The Working Party on Severe Aplastic Anemia of the EBMT studied the impact of time on outcomes for unrelated donor BMT for SAA. This figures shows the cumulative 5-year survival for those transplanted before 1998 (32%) compared with those after 1998 (57%), with the differences being highly statistically significant. Source: Viollier et al.
14
Copyright Nature Publishing Group.
SCT for severe aplastic anemia G Meyers and RT Maziarz Table 2 Outcomes of SAA patients treated with fludarabine containing conditioning regimens overall context of patient outcomes. The key studies that have compared allogeneic HSCT with IST and how current strategies may impact the considerations for treatment are described below. The largest study comparing allogeneic HSCT with IST was a retrospective analysis of over 2400 patients with SAA treated in Europe from 1991 to 2002. 30 Frontline treatment for patients presenting with SAA was compared and outcomes were examined. In addition, critical factors that determine these outcomes were identified. This study generated some important conclusions (1) significant improvements in alternative donor transplants have occurred over time, whereas outcomes from treatment with immunosuppression have not improved; (2) early initiation of therapy is vital; and (3) age is an important factor. Overall, improved outcomes with transplant were identified compared with IST, but with the recognition that the majority of patients undergoing the HSCT procedure had matched sibling donors. Table 3 outlines the recent major studies of nontransplant immunosuppression for SAA, highlighting important outcomes and consequences of this treatment. Treatment with IST, as compared with treatment with HSCT, is associated with a high rate of relapsed disease and secondary hematological malignancies. The rates of relapse reported in these major studies ranges from 9 to 42%, with many of the higher rates found in studies that have prolonged follow-up, as the relapse risk never extinguishes. As a consequence, the most current recommendation for IST treatment include a very slow taper of CYA 31 and acknowledgement that a significant number of patients will require long-term use of CYA or other immune suppressive agents to maintain transfusion independence. A second significant concern is the development of clonal hematopoietic disorders, in particular paroxysmal nocturnal hemoglobinuria, myelodysplasia and leukemia. Those rates vary between 5 and 25%, with the highest rates being reported from those studies that had the longest patient follow-up. More importantly, the cumulative incidence of secondary clonal diseases does not reach a plateau over time. 10, 11 Given these factors, IST may prove to be inferior in the long-term when compared with HSCT and may lead investigators to favor early HSCT consideration not only in those with an HLA-matched related donor but also in those young patients with a well-matched, unrelated donor.
How does matched related allogeneic transplantation compare with alternative donor transplantation?
A prospective, direct comparison of outcomes of HLAmatched sibling with well-matched, unrelated donor HSCT for SAA has never been performed. However, in a pediatric patient cohort, a retrospective analysis was performed, with the provocative finding of comparable results between matched donor and alternative donor transplants for children with SAA. 32 Kennedy-Nasser et al. compared outcomes from 36 patients who had received transplants from either matched sibling donors (n ¼ 15) or alternative donors (n ¼ 21). All patients who received an alternative donor transplant had failed previous immunosuppressive therapy, and 19/23 received reduced-intensity conditioning Table 3 Recent studies of immune suppressive therapies on outcomes of SAA patients regimens with CY and low-dose TBI combined with either fludarabine or alemtuzumab. Although higher rates of GVHD were seen in the alternative donor group, the 4-year survival in the two groups was comparable, with 93% survival in the matched sibling group and 89% survival in the alternative donor group. Differences in long-term complications have not been determined, but the data from this study are still maturing, as the median follow-up in this study is 52 months (range 6-99 months). Whether current outcomes in unrelated donor transplantation in the adult SAA population are equivalent to those in sibling transplants remain unclear, although similar observations for improved outcomes with unrelated donor HSCT have been made in adults with malignant hematological disorders. 33 In reviewing alternative donor transplantation for aplastic anemia, one must also review the current status of cord blood transplantation for SAA. Since 1988, when the first cord blood transplant was successfully performed on a patient with Fanconi anemia, 34 the utilization of cord blood for malignant and nonmalignant disorders has flourished, with over 3000 such procedures performed to date with the assistance of the National Marrow Donor Program (http://www.marrow.org/). With malignant disorders and use of myeloablative regimens, establishment of full donor chimerisms and robust engraftment has been found. However, use of cord blood transplants in nonmalignant diseases, in particular SAA, still faces the challenge of optimizing the conditioning regimen to enhance engraftment rates. As reported first by Neudorf et al. 35 in 1995, despite conditioning with regimens that are typically highly effective in facilitating engraftment in SAA, failure to establish donor hematopoiesis has been a complication in cord blood transplants for SAA. Many groups [36] [37] [38] [39] [40] [41] [42] [43] are working to optimize conditioning regimens and cord blood product qualities to ensure engraftment within the confines of minimizing the known high risk of infectious complications with this type of transplant.
Timing from diagnosis to transplant Many studies have clearly shown the critical need for early treatment in SAA, with the goal of instituting frontline therapy within 2 months of the diagnosis. In focusing on timing of transplant, many groups have shown that a reduced time to transplant is beneficial in overall outcomes. Many factors influence these observations, including degree of transfusion support, immunosuppression before transplant, infectious complications before transplant and performance status at the time of transplant. In the early analysis of registry data in matched sibling transplants for SAA by Gluckman et al., 44 the analysis of transfusion burden before transplant found that 420 transfusions before transplant significantly negatively impacted outcomes. This review also discovered that an interval of more than 1 month between diagnosis and transplant negatively impacted outcomes. These findings have been verified by additional studies of factors impacting outcomes in unrelated donor HSCT and matched sibling HSCT in SAA. 30, 45 Therefore, early initiation of an unrelated donor search and prompt decision to pursue alternative donor HSCT are key factors in maximizing outcomes, as detailed in Table 4 .
Would the outcomes for unrelated donor HSCT be improved if up front transplants were performed? This is a relevant question, but one that cannot be answered with the current available information. One must recognize that the negative outcomes associated with unrelated HSCT are influenced by a selection bias, such that the procedures are generally performed late in the disease, and after failed IST and often in the setting of deep-seated infection. In our own single institutional experience, for example, a patient with SAA and an apical pulmonary aspergillus mass underwent HSCT as a desperate maneuver to restore normal hematopoiesis, to allow the potential for either lobectomy or pneumonectomy. This patient reached engraftment, but 26 days after unrelated HSCT and before the target operative date of 35-42 days post transplant, exsanguinated from direct invasion of the aspergillus infection into the subclavian artery. This anecdote is not an uncommon scenario in tertiary transplant centers and these type of cases will always negatively influence retrospective outcome analyses.
The priority of application of alternative donor HSCT in the treatment of SAA should change, given the improvements in outcomes with this therapy. Yet, despite these effects, it should still be acknowledged that time to transplantation still has a significant impact on OS in all large studies. Therefore, early HSCT should be considered part of standard of care for those patients who have failed one round of IST. Importantly, initiation of an unrelated donor search should occur concomitantly with the institution of immunosuppression. If a suitable donor is identified and an unsatisfactory response to therapy has occurred, then transplantation can be immediately pursued. This treatment algorithm has been adopted by our transplant community for newly diagnosed patients with acute leukemia with poor risk factors, as standard of care. In the patients with SAA, it may only make sense to follow the same path, as we find that long-term outcomes of matched unrelated BMT continue to approach outcomes of matched related transplantation. 
Summary and recommendations for change
The management of aplastic anemia after failure or partial response to a first cycle of immunosuppression is challenging, yet to date, the accepted treatment algorithm has been driven by the opinion that a BMT using an unrelated donor is riskier than continued failure to reconstitute hematopoiesis. As we have outlined in this review, this opinion is no longer valid, as unrelated donor BMT for aplastic anemia has rapidly evolved into a safe and effective procedure, mainly through the use of reduced-intensity conditioning regimens and high-resolution typing of donors. Therefore, the time is ripe for modulating our approach to patients with aplastic anemia who do not have a matched related donor. Table 4 outlines the pros and cons of early transplantation in this patient group. With these considerations in mind, we recommend the following:
1. High-resolution typing of the patient and initiation of an unrelated donor search at the time of initiating immunosuppression. 2. If the patient has little or no response to immunosuppression by 12 weeks and a suitable unrelated donor is identified, then proceed directly to an unrelated donor BMT using either reduced-intensity or myeloablative regimen.
Only if a suitable donor is not identified or logistics
impede moving forward with a transplant, a second round of immunosuppression should be pursued.
These recommendations that we have developed are completely consistent with the newly published recommendations by the British Committee for Standards in Haematology, 46 and recognize the advances within the field of unrelated transplantation for SAA. The marked improvements in unrelated donor HSCT must be integrated into our practice, and must drive our recommendations, with the goal of maximizing patient care. Ideally, this effort would be pursued in context of a prospective, randomized, controlled trial, but the current reality is that with this rare disease, the development of such a trial is unlikely to occur within the next half decade.
